MondegarAI
PFIZER INC (PFE)

Q1 2026 · 13F-HR

PFIZER INC (PFE)holdings as filed

Filed 2026-05-12 · accession 0000078003-26-000064

$238.8M
Reported value
18
Positions
2026-03-31
Period end
View analyzed profile →PRO

The Brief · PFIZER INC (PFE) · Q1 2026

AI · grounded in 13F

PFIZER INC (PFE) closed its position in AN2 THERAPEUTICS INC ANTX, reducing its holdings by $815,436. The fund established a new position in AGOMAB THERAPEUTICS NV AGMB valued at $813,750. Additionally, the fund trimmed its stake in Q32 BIO INC QTTB by 63.42% and reduced its holding in CELCUITY INC CELC by 15.38%.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
68622P109ORICORIC PHARMACEUTICALS INC$57.7M24.1%4,780,401CommonSOLE
019770106ALLOALLOGENE THERAPEUTICS INC$49.8M20.9%22,032,040CommonSOLE
04335A105ARVNARVINAS INC$34.9M14.6%3,457,815CommonSOLE
15102K100CELCCELCUITY INC$31.3M13.1%295,652CommonSOLE
G9TY5A101ZURAZURA BIO LTD$16.8M7.05%2,838,913CommonSOLE
Y95308105WVEWAVE LIFE SCIENCES LTD$11.9M5.00%1,875,000CommonSHARED
747324101PYXSPYXIS ONCOLOGY INC$9.2M3.86%7,032,770CommonSOLE
142038108CRBUCARIBOU BIOSCIENCES INC$8.3M3.50%4,690,431CommonSOLE
84833T103SPROSPERO THERAPEUTICS INC$5.5M2.31%2,362,348CommonSOLE
G1110E107BHVNBIOHAVEN LTD$4.2M1.77%505,645CommonSOLE
14147L108CRDFCARDIFF ONCOLOGY INC$3.7M1.57%2,411,575CommonSOLE
98943L107ZNTLZENTALIS PHARMACEUTICALS INC$2.0M0.84%953,834CommonSOLE
65343E207NXTCNEXTCURE INC$1.5M0.64%153,354CommonSOLE
00860C102AGMBAGOMAB THERAPEUTICS NV$813,7500.34%75,000CommonSOLE
746964105QTTBQ32 BIO INC$736,7310.31%101,618CommonSOLE
097702203BOLTBOLT BIOTHERAPEUTICS INC$137,1160.06%31,305CommonSHARED
37611X209DNAGINKGO BIOWORKS HOLDINGS INC$17,3630.01%2,928CommonSOLE
81727U105SENS1GBPSENSEONICS HLDGS INC$14,2420.01%2,171CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.